Hologic and Inpeco Announce Co-Marketing Partnership to Advance Molecular Laboratory Automation
20.10.2026 15:00:00 EEST | Business Wire | Press release
Hologic, Inc., a global leader in women’s health and diagnostics, and Inpeco S.A., the global leader in Total Laboratory Automation, today announced they have signed a co-marketing partnership for Inpeco’s automation solution FlexLab™ X and Hologic’s Panther® System in Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020837126/en/
Hologic and Inpeco S.A. announce a co-marketing partnership for Inpeco's automation solution FlexLab™ X and Hologic’s Panther® System in Europe.
Inpeco’s recently launched FlexLab X system enables laboratories to connect multiple Panther Systems. By combining Hologic’s fully-automated molecular diagnostics platform with FlexLab X‘s open automation capabilities, laboratories can achieve high-throughput workflows with the potential to increase sample volumes1 and enhance end-to-end sample traceability2, supporting reliable test results for optimal patient outcomes.3 The Panther System will integrate seamlessly into advanced, fully tracked automation environments, helping high‑throughput molecular laboratories work more efficiently and enhance productivity.1,3,4
“Through our co-marketing partnership with Inpeco, we are helping molecular laboratories take the next step in automation by connecting Hologic’s proven Panther System with Inpeco’s advanced automation technology,” said Frédérique Gallis, Vice President, International Sales and Marketing at Hologic. “Together, we can help customers streamline workflows, increase throughput and enhance pre- and post-analytical sample traceability. This partnership reflects our commitment to delivering scalable solutions that support laboratories as they manage growing testing demands and prepare for the future of molecular diagnostics in an increasingly competitive environment.”
“At Inpeco, we see automation as a key driver of the future of laboratories, through fully automated, touchless and traceable diagnostic processes that begin outside the lab and extend inside,” said Riccardo Triunfo, CEO of Inpeco. “As molecular testing expands, laboratories require solutions that can manage increasing complexity while maintaining performance and reliability. With over 30 years of experience in laboratory automation, we are proud to bring our expertise to this important field. Our partnership with Hologic reflects our common dedication to innovation and our shared goal: helping laboratories embrace the future of molecular diagnostics with high performance and reliability.”
More information about Hologic’s Panther Scalable Solutions can be found here.
More information about Inpeco’s FlexLab X systems can be found here.
About Hologic
Hologic, Inc. is a global leader in women’s health dedicated to developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world. To learn more, visit www.hologic.com and connect with us on LinkedIn, Facebook, X, Instagram and YouTube.
About Inpeco
Inpeco is the global leader in Total Laboratory Automation. The company’s game-changing solutions combine open connectivity with full sample traceability to support secure test results and increase productivity in clinical laboratories around the world. To date, more than 2800 Inpeco systems have been shipped to 78 countries. Inpeco also provides automation for anatomical pathology labs and is developing solutions for blood banks and life sciences applications. The Group is headquartered in Novazzano, Switzerland, and operates a development and manufacturing facility in Italy, as well as sales offices in Europe, the United States, and China.
Forward-Looking Statements
This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.
Hologic, The Science of Sure and Panther are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
FlexLab is a trademark of Inpeco SA.
References
- Inpeco. Why Lab Automation. https://www.inpeco.com/why-lab-automation/ Last accessed 15 Jul 26.
- Inpeco. FlexLab™ X. https://www.inpeco.com/our-automation-solutions/lab-automation-system/flexlab-x/ Last accessed 15 Jul 26.
- Kim K, Lee SG, Kim TH, et al. Economic Evaluation of Total Laboratory Automation in the Clinical Laboratory of a Tertiary Care Hospital. Ann Lab Med, 2022 Jan 1;42(1):89-95.
- Chih-Wei Tseng, Ying-Chun Li, Herng-Sheng Lee, et al. Laboratory testing consolidation and total laboratory automation improves service efficiency and effectiveness: a study of a medical centre in Taiwan. Laboratory Medicine, November 2024:55 (6):677–685.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261020837126/en/
Contacts
Hologic Media Contact:
Bridget Perry
Senior Director, Corporate Communications
(+1) 508.263.8654
bridget.perry@hologic.com
Inpeco Media Contact:
Markus J. Gross
Head Global Marketing
Markus.Gross@inpeco.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ARIS Launches Process Context for Enterprise AI, Reinforcing Position as the Essential Platform for AI Ecosystem20.10.2026 15:00:00 EEST | Press release
ARIS, the pioneer in business process management whose powerful Enterprise Model has been the foundation for enterprise operations for more than three decades, today launched Process Context for Enterprise AI – to become the critical base layer for the agentic ecosystem, giving agents and applications the business understanding they need to deliver measurable new value. While Process Context is becoming critical for successfully deploying and scaling enterprise AI, it demands far more than simply connecting AI agents to business data. It requires a comprehensive foundation that captures the relationships between processes, people, systems, risks and controls. Built on a comprehensive Digital Twin of the Organization that connects how work is designed with the execution data that sits around it, ARIS provides this critical layer of Process Context from more than 30 years of enterprise knowledge and experience, something new entrants to the space are struggling to replicate. The importan
Debiopharm Highlights Clinical Momentum Across DDR Portfolio at ESMO 2026, Advancing WEE1-Based Therapies in Ovarian and Uterine Cancers and Glioblastoma20.10.2026 15:00:00 EEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced their upcoming Phase 1/Phase 2 clinical updates at the European Society for Medical Oncology (ESMO) Congress (Madrid, Spain, 23-27 October). During the event, Debiopharm will highlight clinical updates on its pipeline targeting the DNA Damage Response (DDR), featuring single-agent data on zedoresertib (Debio 0123) as well as rational combination strategies, with both temozolomide in glioblastoma and with lunresertib (Debio2513) in solid tumors. Debiopharm’s planned activities at ESMO 2026 include: Rapid Oral Presentation (Debio 0123-GBM-105 / NCT05765812): Presenting dose escalation data evaluating zedoresertib in combination with temozolomide in patients with recurrent or progressive glioblastoma. Poster Presentation (Debio 0123-102 / NCT05109975): Presenting Phase 1 expansion data evaluating s
Visa, BILL and Billtrust Launch First Live Pilot for Trusted AI Agent Payments Between Buyer and Supplier Platforms20.10.2026 15:00:00 EEST | Press release
Visa (NYSE: V), BILL (NYSE: BILL) and Billtrust today announced they have launched the first live pilot to enable trusted AI agents to initiate and complete approved buyer invoice payments end-to-end through supplier portals. Until now, many payment portals relied on human authentication requirements that limited how approved payments could be automated. Together, with leading accounts payable and receivable solutions providers BILL and Billtrust, the Visa Intelligent CommerceTM portfolio helps bridge that gap. Leveraging offerings such as Visa Trusted Agent Protocol, AI agents can now be securely authenticated to credentialed portals. As a result, buyer payments that previously relied on manual entry can be completed by trusted AI agents, while preserving supplier control and oversight. How trusted AI agents are overcoming one of payment automation’s biggest barriers The flow begins when the authorized BILL Payment Agent — registered using Visa’s Trusted Agent Protocol and Agentic Dir
FiRa Consortium Launches Core 4.1 Specifications and Enhanced Certification Program20.10.2026 15:00:00 EEST | Press release
The FiRa® Consortium today announced the release of the FiRa Core 4.1 Specifications and an updated 4.1 Certification Program to help advance ultra-wideband (UWB) interoperability within the FiRa ecosystem. Core 4.1 introduces enhancements for FiRa Untracked Navigation, expanded cryptographic security certification, and additional support for concurrent ranging and data capabilities across multi-vendor FiRa deployments. The release supports deployment requirements defined by the FiRa Frameworks and Profiles Sub-Group (FPSG), including high-density indoor positioning, hardware-level security, and concurrent data capabilities for FiRa use cases. Features of the FiRa Core 4.1 Specifications and Certification Program Enhanced Downlink Time Difference of Arrival (DL-TDoA) for FiRa Untracked Navigation — Adds coordinate-system and anchor-location encoding options, including floor identification without increasing message size, with certification coverage for these options and cross-cluster s
Parse Biosciences Launches Evercode MAX, Enabling Researchers to Profile More Cells and Samples with Greater Flexibility20.10.2026 15:00:00 EEST | Press release
Parse Biosciences, the leading provider of scalable and accessible single cell sequencing and a QIAGEN company, today announced that Evercode™ MAX, a modular configuration of its flagship Evercode single cell sequencing platform, is now shipping to customers. Using the same instrument-free workflow, researchers can profile up to 2.5 times as many cells across up to twice as many samples within their existing budget, or run the same experiment at roughly half the overall cost. Evercode MAX enables researchers to build a kit configuration around their experiment, with sample barcoding and library preparation as independent kits. Evercode MAX is available for Whole Transcriptome, WT FFPE, TCR, BCR, and CRISPR Detect. With configurations supporting up to 384 samples and 2 million cells, researchers can prioritize more samples to characterize biological variation or more cells per sample to resolve rare populations and subtle cell states. That flexibility extends to value as well. Because E
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom